Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform
Authors:
- Wang ZhangWZWang Zhang
- Mingzhu YinMYMingzhu Yin
- Tao ZhangTZTao Zhang
- Xiaoyan WuXWXiaoyan Wu
- Haiyu ZhangHZHaiyu Zhang
- Meng SunMSMeng Sun
- Zhenzi LiZLZhenzi Li
- Yan HouYHYan Hou
- Xiaohua ZhouXZXiaohua Zhou
- Ge LouGLGe Lou
- Kang LiKLKang Li
- 27 January 2012
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 51 (4) , 473-479
Abstract
Currently available tests are insufficient to distinguish patients with epithelial ovarian cancer (EOC) from normal individuals. Metabolomics, a study of metabolic processes in biologic systems, has emerged as a key technology in the measurements of small molecular metabolites in tissues or biofluids. To investigate the application of metabolomics on selecting EOC-associated biomarkers, 173 plasma specimens (80 newly diagnosed EOC patients and 93 normal individuals) were analyzed using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC/QTOF/MS). A two-step strategy was performed to select EOC-associated biomarkers. The first step was to select potential biomarkers in distinguishing 42 cancer patients from 58 normal controls through partial least-squares discriminant analysis (PLS-DA) and database searching, and the second step was to validate the discrimination performance of these biomarkers in a dataset contained 38 EOCs and 35 controls. Eight candidate biomarkers were selected. The combination of these biomarkers resulted in the area of receiver operating characteristic curve (AUC) of 0.941, a sensitivity of 0.921, and a specificity of 0.886 at the best cut-off point for detecting EOC. Our findings suggested that sharp differences in metabolic profiles exist between EOC patients and normal controls. The identified eight metabolites associated with EOC may be served as novel biomarkers for diagnosis.Keywords
This publication has 25 references indexed in Scilit:
- Combination of CA125 and RECAF biomarkers for early detection of ovarian cancerTumor Biology, 2011
- Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography–mass spectrometryAnalytica Chimica Acta, 2011
- Diagnosis of Early Stage Ovarian Cancer by1H NMR Metabonomics of Serum Explored by Use of a Microflow NMR ProbeJournal of Proteome Research, 2011
- Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastasesBritish Journal of Cancer, 2010
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature, 2009
- Clinical Applications of Metabolomics in Oncology: A ReviewClinical Cancer Research, 2009
- Symbiotic gut microbes modulate human metabolic phenotypesProceedings of the National Academy of Sciences, 2008
- Lysophosphatidic Acid Acyltransferase-β Is a Prognostic Marker and Therapeutic Target in Gynecologic MalignanciesCancer Research, 2005
- Enzymes of Sphingolipid Metabolism: From Modular to Integrative SignalingBiochemistry, 2001
- Early detection of ovarian cancerCA: A Cancer Journal for Clinicians, 1995